Last reviewed 2026-05-14 · How we verify

Fluticasone Discus 250 µg

Fluticasone propionate is a corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors and suppressing inflammatory mediator release.

Fluticasone propionate is a corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors and suppressing inflammatory mediator release. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.

At a glance

Mechanism of action

Fluticasone propionate is a potent inhaled corticosteroid that acts as a glucocorticoid receptor agonist in the lungs. It suppresses the production and release of inflammatory cytokines, chemokines, and adhesion molecules, thereby reducing airway inflammation, mucus production, and bronchial hyperresponsiveness. The Discus formulation is a dry powder inhaler delivering 250 µg per actuation for maintenance therapy of asthma and COPD.

Approved indications

• Asthma maintenance therapy
• Chronic obstructive pulmonary disease (COPD) maintenance therapy

Common side effects

• Tremor
• Headache
• Palpitations
• Muscle cramps
• Nervousness
• Oral candidiasis

Key clinical trials

• Impact of Fluticasone and Salmeterol on Airway Dendritic Cells (DCs) in Smokers (PHASE1)
• DESOLO - SiT Peri-Launch: A Comparison of Symbicort Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma in Adults (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Fluticasone Discus 250 µg CI brief — competitive landscape report
• Fluticasone Discus 250 µg updates RSS · CI watch RSS
• AstraZeneca portfolio CI